These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17596568)

  • 41. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study.
    Björk J; Johansson B; Broberg K; Albin M
    Leuk Res; 2009 Jun; 33(6):788-91. PubMed ID: 19019430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
    Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
    Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Trilineage myelodysplasia].
    Kuriyama K
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):209-12. PubMed ID: 9851123
    [No Abstract]   [Full Text] [Related]  

  • 45. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
    Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
    Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incremental gains and a long road ahead in MDS.
    Steensma DP; Tefferi A
    Oncology (Williston Park); 2008 Nov; 22(12):1352, 1358, 1360. PubMed ID: 19320067
    [No Abstract]   [Full Text] [Related]  

  • 47. Advances in the treatment of MDS, multiple myeloma, and CLL.
    Snively A
    ONS Connect; 2007; 22(8 Suppl):55-6. PubMed ID: 17824566
    [No Abstract]   [Full Text] [Related]  

  • 48. [Myelodysplastic syndromes: clinically relevant aspects in diagnosis, prognosis and prediction].
    Noesslinger T; Pfeilstoecker M
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2086-90. PubMed ID: 18985562
    [No Abstract]   [Full Text] [Related]  

  • 49. [Hematology in the elderly patient: is there progress? 42nd Congress of the French National Society of Internal Medicine in Provence--8-10 June 2000].
    Renou P
    Presse Med; 2000 Sep; 29(27):1517-9. PubMed ID: 11045123
    [No Abstract]   [Full Text] [Related]  

  • 50. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes.
    Schiffer CA
    Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular bases of myelodysplastic syndromes: lessons from animal models.
    Komeno Y; Kitaura J; Kitamura T
    J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
    Boruchov AM
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S37-43. PubMed ID: 19245933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. More on polymyalgia rheumatica (PMR) as a paraneoplastic rheumatic syndrome in the elderly (bicytopenia and PMR preceding acute myeloid leukemia).
    Anton E
    J Clin Rheumatol; 2007 Apr; 13(2):114. PubMed ID: 17414547
    [No Abstract]   [Full Text] [Related]  

  • 56. Myelodysplastic syndrome in children and adolescents.
    Niemeyer CM; Baumann I
    Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.
    Chamseddine AN; Jabbour E; Kantarjian HM; Bohannan ZS; Garcia-Manero G
    Curr Oncol Rep; 2016 Jan; 18(1):4. PubMed ID: 26700507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two cases assessed for myeloid disorders had an unexpected twist.
    Reddy KS
    Cancer Genet Cytogenet; 2008 Mar; 181(2):138-40. PubMed ID: 18295667
    [No Abstract]   [Full Text] [Related]  

  • 60. Atypical features of primary myelodysplastic syndrome.
    Pati H; Bhargava M; Kochupillai V
    Indian J Med Res; 1986 Nov; 84():516-8. PubMed ID: 3470255
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.